GlassScriptPhysician profile
Skylar Michelle Bluebird
NPI 1245817733
$4,792.44
in general payments reported to CMS, 2019-2025
39 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $625 · 2023: $1,549 · 2024: $1,131 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,017.44 | 2021-2025 | |
| Abbott Laboratories | $501.16 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Confirm Rx |
| Novo Nordisk INC | $449.71 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $303.51 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $251.55 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $239.85 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $230.81 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $214.94 | 2023-2025 | Apretude |
| Antares Pharma, INC. | $176.16 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Amarin Pharma, INC. | $152.24 | 2021-2023 | |
| Pfizer INC. | $136.17 | 2023-2025 | |
| Exact Sciences Corporation | $105.48 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $99.59 | 2021-2023 | Belsomra, Steglatro |
| Idorsia Pharmaceuticals US INC | $94.07 | 2022-2024 | Quviviq |
| Amgen INC. | $83.39 | 2022-2025 | Repatha, Otezla, Otezla |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cleerly, INC. | $71.56 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Seqirus USA INC | $65.50 | 2024-2025 | Fluad, Flucelvax |
| Biotronik Nro, INC. | $64.11 | 2023 | Biotronik |
| Sanofi Pasteur INC. | $55.76 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.50 | 2022 | |
| Azurity Pharmaceuticals, INC. | $51.47 | 2024-2025 | Horizant, Azmiro, Edarbyclor |
| Otsuka America Pharmaceutical, INC. | $42.10 | 2024-2025 | Rexulti |
| Genentech USA, INC. | $37.17 | 2021-2022 | |
| Axsome Therapeutics, INC. | $35.91 | 2025 | Auvelity |
| Boston Scientific Corporation | $27.70 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Acella Pharmaceuticals, LLC | $23.96 | 2024 | NP Thyroid 60 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.73 | 2025 | |
| Philips North America LLC | $18.71 | 2024 | (Ck7) Extended Holter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.39 | 2024 | Xifaxan, Trulance |
| Mayne Pharma Commercial LLC | $17.84 | 2025 | |
| Dexcom, INC. | $16.50 | 2025 | Dexcom G6 Transmitter |
| Corium, LLC | $15.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.62 | 2024 | Zoryve |
| Medtronic, INC. | $15.08 | 2025 | Venaseal |
| Sanofi-Aventis U.S. LLC | $14.85 | 2022 | |
| Halozyme INC | $14.46 | 2023 | |
| Tolmar, INC. | $13.96 | 2025 | Jatenzo |
| Lundbeck LLC | $13.48 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skylar Bluebird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.